Welcome to our dedicated page for Quoin Pharmaceuticals, Ltd. American Depositary Shares news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals, Ltd. American Depositary Shares stock.
Quoin Pharmaceuticals Ltd. (symbol: QNRX) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. Founded with a commitment to addressing unmet medical needs, Quoin focuses on innovating treatments that can make a significant impact on patients’ lives.
Quoin’s research and development pipeline includes potential treatments for a range of conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa. Their work is particularly focused on Netherton Syndrome, a rare genetic disorder characterized by defective skin barrier function.
Recently, Quoin made significant strides in its clinical studies for Netherton Syndrome. Protocol amendments, based on initial positive data, were approved by the FDA and include increasing study sizes, modifying dosing frequencies, and broadening eligibility criteria. These changes aim to enhance the potential for a successful outcome.
Furthermore, Quoin expanded its intellectual property portfolio by filing both US and international patent applications for a novel combination product to treat Netherton Syndrome. They are also exploring additional patent opportunities related to the clinical and manufacturing aspects of their products.
Financially, Quoin has strengthened its position through a successful public offering and the execution of an equity line of credit arrangement, extending their cash runway into late 2025. This financial stability supports the company as it pursues key milestones in its development pipeline.
Under the leadership of Dr. Michael Myers, Quoin Pharmaceuticals is poised to make significant advancements in the field of rare and orphan disease treatments. The company continues to engage with the investment community and stakeholders through various communication channels, ensuring transparency and building investor confidence.
To stay updated on Quoin Pharmaceuticals' latest developments, visit their website or follow them on LinkedIn.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has submitted a Scientific Advice Briefing Document to the European Medicines Agency (EMA) for QRX003, aimed at treating Netherton Syndrome, a rare genetic disease with no current cure. This submission is a critical first step towards advancing the treatment into clinical testing and potential commercialization in the EU. The company has integrated previous feedback received from the FDA into this submission, reflecting its commitment to addressing unmet medical needs in rare diseases.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has expanded its partnership with ER-Kim to include six additional countries for the commercialization of QRX003, a treatment for Netherton Syndrome. This new agreement adds Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta to the existing fifteen countries covered in the initial agreement. With this expansion, Quoin now has a total of 60 countries under distribution agreements for QRX003, which aims to be the first approved treatment for this rare genetic disorder lacking current therapies.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive agreement with Neopharm Medical Supplies to commercialize its investigational drug QRX003 in Israel. This marks the sixth distribution partnership for QRX003 since Quoin's NASDAQ debut in October 2021. The agreement aims to address Netherton Syndrome, a rare genetic disorder with no existing treatment. Quoin's CEO, Dr. Michael Myers, emphasized the importance of expanding the distribution network to ensure global access for patients once the product is approved.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive distribution agreement with ER-Kim to commercialize its investigational treatment QRX003 across 15 Central and Eastern European countries. This marks Quoin's fifth distribution partnership since its public debut in October 2021, expanding its access to Netherton Syndrome patients in crucial regions. With this agreement, Quoin now has partnerships in a total of 53 countries, reaffirming its commitment to providing treatment options for this rare genetic disease.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a new exclusive Distribution Agreement with OrphanDC for QRX003, aimed at treating Netherton Syndrome, in Brazil, Argentina, and Colombia. This marks the fourth distribution partnership since going public in October 2021. Quoin will supply QRX003 to OrphanDC under a revenue-sharing model. The company has previously secured agreements for other regions, including the Middle East and North Africa, and continues discussions with additional distributors. Netherton Syndrome is a rare genetic disorder with no current cure.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced an exclusive Distribution Agreement with Orpharm LLC for the commercialization of QRX003 in Russia and CIS, intended for treating Netherton Syndrome. This agreement marks the third partnership for QRX003 in two months and reflects Quoin's commitment to increasing patient access. QRX003 is crucial as there are currently no approved treatments for this severe genetic disease. Quoin will supply the product to Orpharm upon regulatory approval.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has signed an exclusive License and Distribution Agreement with Genpharm Services for its investigational treatment QRX003, intended for Netherton Syndrome. Genpharm will commercialize QRX003 in the Middle East and North Africa upon receiving regulatory approvals. This agreement marks Quoin's second licensing deal for QRX003 and includes a revenue-sharing arrangement. Quoin is committed to developing therapies for rare diseases, targeting significant unmet medical needs.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has signed an exclusive License and Distribution Agreement with AFT Pharmaceuticals for QRX003, targeting Netherton Syndrome in Australia and New Zealand. Quoin will receive a 20% royalty on net sales post-regulatory approval. This marks QRX003's first licensing agreement, highlighting Quoin's strategy in rare diseases. AFT's commercial presence and focus on dermatology are expected to enhance product promotion. Currently, Netherton Syndrome has no approved treatments, emphasizing the potential impact of QRX003.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has appointed Gordon Dunn as Chief Financial Officer, effective immediately. With over 30 years of experience, Dunn has held CFO roles in both private and publicly traded companies, including Qured and Innocoll AG. Dr. Michael Myers, CEO of Quoin, expressed confidence in Dunn's capabilities, emphasizing his background in investment banking and private equity. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a promising pipeline targeting conditions like Netherton Syndrome and Epidermolysis Bullosa.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a partnership with Queensland University of Technology for an exclusive option on a bi-functional protein targeting Netherton Syndrome. The agreement entails funding a pre-clinical program, with an option for an exclusive global license upon completion. No upfront fees are required, but royalties will apply upon product approval. CEO Dr. Michael Myers emphasized that this complements their lead asset, QRX003, further solidifying their commitment to developing treatments for rare diseases.
FAQ
What is the current stock price of Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX)?
What is the market cap of Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX)?
What is Quoin Pharmaceuticals?
What diseases is Quoin Pharmaceuticals targeting?
What are the recent achievements of Quoin Pharmaceuticals?
Who is leading Quoin Pharmaceuticals?
How can I stay updated on Quoin Pharmaceuticals' news?
What is Netherton Syndrome?
What financial strategies has Quoin Pharmaceuticals implemented recently?
What is unique about Quoin Pharmaceuticals' approach?
Are Quoin Pharmaceuticals' statements forward-looking?
Where is Quoin Pharmaceuticals listed?
